The Benefits And Risks Of An LLC Business Model In Biotech
Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey
After two Big Pharma deals, Nimbus looks to keep the hits coming
After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug
Biotech’s top money raisers of 2023
Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year
AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma
Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study
Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup
In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront
